戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y end point was to compare overall survival (Kaplan-Meier analysis).
2 were 6.5% and 6.7%, respectively (unadjusted Kaplan-Meier analysis).
3 84% for pre-LT and 93% for post-LT patients (Kaplan-Meier analysis).
4 corneal thickness (CCT), and graft survival (Kaplan-Meier analysis).
5 d 71% at 1, 3, and 5 years, respectively, by Kaplan Meier analysis.
6                     Survival was analyzed by Kaplan-Meier analysis.
7 al of bladder cancer patients as revealed by Kaplan-Meier analysis.
8 ation of reduced recurrence-free survival by Kaplan-Meier analysis.
9 999 copies/mL) for 6, 9, or 12 months, using Kaplan-Meier analysis.
10 tive risk (lambda) and cumulative risk using Kaplan-Meier analysis.
11 number of photographs taken was evaluated by Kaplan-Meier analysis.
12  stable microsatellites P = .0415), based on Kaplan-Meier analysis.
13  rates divided by incidence, as estimated by Kaplan-Meier analysis.
14 tional hazards regression model analysis and Kaplan-Meier analysis.
15 rvival (PFS) and overall survival (OS) using Kaplan-Meier analysis.
16 ion-free survival and overall survival using Kaplan-Meier analysis.
17                  Survival was assessed using Kaplan-Meier analysis.
18 us immunosuppressant use was estimated using Kaplan-Meier analysis.
19 ar cumulative percentage of MAE was 12.5% by Kaplan-Meier analysis.
20 cause-specific survival (CSS), P = 0.012] by Kaplan-Meier analysis.
21 al hazards modeling and were evaluated using Kaplan-Meier analysis.
22 tuarial overall survival was calculated with Kaplan-Meier analysis.
23          Long-term survival was evaluated by Kaplan-Meier analysis.
24 m the first TACE session was calculated with Kaplan-Meier analysis.
25 cumulative incidence of PD was calculated by Kaplan-Meier analysis.
26 tients was assessed using Cox regression and Kaplan-Meier analysis.
27 dney transplants at the same center by using Kaplan-Meier analysis.
28 tients was assessed using Cox regression and Kaplan-Meier analysis.
29                   Survival was determined by Kaplan-Meier analysis.
30 atus, and time to recurrence on the basis of Kaplan-Meier analysis.
31 elopment of metastases was analyzed by using Kaplan-Meier analysis.
32 n 1 year of transplantation were assessed by Kaplan-Meier analysis.
33 ranslocation in human PNI was analyzed using Kaplan-Meier analysis.
34                   Survival was determined by Kaplan-Meier analysis.
35  and HIV-1-free survival were assessed using Kaplan-Meier analysis.
36 g-donor KTA or with a LKTx was obtained from Kaplan-Meier analysis.
37 ecreased patient and graft survival rates by Kaplan-Meier analysis.
38 which was significant in both chi-square and Kaplan-Meier analysis.
39  (+/- distant metastasis) were calculated by Kaplan-Meier analysis.
40 n rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.
41 ative risk of treatment failure by day 28 by Kaplan-Meier analysis.
42 associated genetic variants were assessed by Kaplan-Meier analysis.
43 he recurrence-free curve was estimated using Kaplan-Meier analysis.
44 d probability of rebound and resistance with Kaplan-Meier analysis.
45 splantation graft survival was assessed with Kaplan-Meier analysis.
46 oth univariate and multivariate analysis and Kaplan-Meier analysis.
47 A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis.
48         Device longevity was estimated using Kaplan-Meier analysis.
49                 The patency was evaluated by Kaplan-Meier analysis.
50 th graft survival was also explored by using Kaplan-Meier analysis.
51 ression analysis (37.4%) or the results of a Kaplan-Meier analysis (10.5%).
52 e who did not have angiography, according to Kaplan-Meier analysis (281/3085 [12.8%] vs 480/4158 [16.
53                                           By Kaplan-Meier analysis, 5-year survival was 35.7% (95% co
54                                   By using a Kaplan-Meier analysis, a person's cumulative probability
55  median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier analysis, a significant nonlinear associati
56                                              Kaplan-Meier analysis also showed that freedom from 50%
57                                         In a Kaplan-Meier analysis, amyloid positive subjects with mi
58 overall survival discrimination, with use of Kaplan Meier analysis and a univariate Cox proportional
59 nt recipients 61 years of age or older using Kaplan- Meier analysis and Cox proportional hazard model
60 ters and survival time was assessed by using Kaplan-Meier analysis and a Cox proportional hazards mod
61  to cancer in the two groups was compared by Kaplan-Meier analysis and a Cox proportional-hazards mod
62 ed time to progression was assessed by using Kaplan-Meier analysis and a Cox regression model.
63 se Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covar
64 sed mortality within 90 days of operation by Kaplan-Meier analysis and assessed the role of patient a
65                        We analysed events by Kaplan-Meier analysis and compared groups with a Cox pro
66 ated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysi
67 tality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox proportional hazard models
68 s and survival outcomes were investigated by Kaplan-Meier analysis and Cox proportional hazard models
69                                      We used Kaplan-Meier analysis and Cox proportional hazard models
70  Recurrence and survival were analyzed using Kaplan-Meier analysis and Cox proportional hazards model
71                                              Kaplan-Meier analysis and Cox proportional hazards regre
72                  Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regre
73                                              Kaplan-Meier analysis and Cox proportional hazards regre
74        Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis.
75                                              Kaplan-Meier analysis and Cox regression models were use
76 idence of clinical outcome was determined by Kaplan-Meier analysis and Cox regression was used to eva
77                                              Kaplan-Meier analysis and Cox regression were used to ev
78                                              Kaplan-Meier analysis and Cox regression were used to se
79         Survival analysis was performed with Kaplan-Meier analysis and Cox regression.
80                                              Kaplan-Meier analysis and Fisher's exact test were used
81                                              Kaplan-Meier analysis and global nonlinear regression re
82                                              Kaplan-Meier analysis and hazard ratios were calculated
83 ere complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.
84          Median ages at LoA were compared by Kaplan-Meier analysis and log-rank test.
85                                           By Kaplan-Meier analysis and log-rank testing, progression-
86                                              Kaplan-Meier analysis and multivariable Cox proportional
87                                   Univariate Kaplan-Meier analysis and multivariate Cox proportional
88        Patient survival was determined using Kaplan-Meier analysis and predictors of mortality were i
89              Survival was evaluated by using Kaplan-Meier analysis and was compared by using Cox prop
90              HCC incidence was determined by Kaplan-Meier analysis, and baseline factors associated w
91   Bi- and multivariable logistic regression, Kaplan-Meier analysis, and Cox proportional hazards mode
92               Disease risk was assessed with Kaplan-Meier analysis, and epidemiologic variables were
93 tical methods included analysis of variance, Kaplan-Meier analysis, and Mantel-Cox proportional hazar
94 mption of continuous smoking was assessed by Kaplan-Meier analysis, and risk differences between grou
95                           Primary patency by Kaplan-Meier analysis at 12 months (360 days) was 86.3%.
96                                       In the Kaplan-Meier analysis at 24 weeks, the rate of death wit
97 s azathioprine was significantly improved by Kaplan-Meier analysis at 4 years (85.61% v. 81.9%).
98 success of second glaucoma drainage devices (Kaplan-Meier analysis) at 1 year, 2 years, and 3 years w
99                                          The Kaplan-Meier analysis based on our patients cohort and t
100                                          The Kaplan-Meier analysis confirmed this result, with a 2-y
101                                In univariate Kaplan-Meier analysis, counts of total (p = 0.010), clas
102 respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regressi
103                                              Kaplan-Meier analysis demonstrated a 5-year OS of 81% in
104                                              Kaplan-Meier analysis demonstrated a cumulative mortalit
105                                              Kaplan-Meier analysis demonstrated a dose-dependent decr
106                                              Kaplan-Meier analysis demonstrated a lower risk for graf
107                                              Kaplan-Meier analysis demonstrated a significant associa
108                                              Kaplan-Meier analysis demonstrated an 88.5% freedom from
109                                              Kaplan-Meier analysis demonstrated an increased risk of
110                                              Kaplan-Meier analysis demonstrated complete success rate
111                                              Kaplan-Meier analysis demonstrated few vision losses dur
112                                              Kaplan-Meier analysis demonstrated significant differenc
113                                     However, Kaplan-Meier analysis demonstrated significantly diminis
114                                              Kaplan-Meier analysis demonstrated significantly greater
115                                              Kaplan-Meier analysis demonstrated that a PFR of <1.4 wa
116                                              Kaplan-Meier analysis demonstrated that a stem cell-like
117                                              Kaplan-Meier analysis demonstrated that ADT users 70 yea
118                                              Kaplan-Meier analysis demonstrated that patients in the
119                                              Kaplan-Meier analysis demonstrated that patients with PV
120                                              Kaplan-Meier analysis demonstrated that patterns of alig
121                                              Kaplan-Meier analysis demonstrated that recurrence predi
122                                            A Kaplan-Meier analysis demonstrated that the 1.6 mA-min d
123                                              Kaplan-Meier analysis demonstrated that the absence of b
124                                              Kaplan-Meier analysis demonstrated that the disease-free
125        Furthermore, the results obtained via Kaplan-Meier analysis demonstrated the potential of radi
126                                            A Kaplan-Meier analysis evaluated the probability and its
127                                           By Kaplan-Meier analysis, event-free survival was significa
128 tumor location demonstrated superior BCSS on Kaplan-Meier analysis for both local stage (node-negativ
129                                              Kaplan-Meier analysis for cumulative patient survival de
130                                   We applied Kaplan-Meier analysis for survival curves and mortality
131                                By unadjusted Kaplan-Meier analysis for the composite end point of dea
132                                          The Kaplan-Meier analysis for time to first patency loss was
133                                              Kaplan-Meier analysis found a 9.7-month difference in me
134                                           By Kaplan-Meier analysis, freedom from AAA rupture was 97.6
135                                           By Kaplan-Meier analysis, freedom from reintervention was 6
136                                           By Kaplan-Meier analysis, HCC incidence was higher, but not
137                                         In a Kaplan-Meier analysis, high baseline ADCC (>median) was
138   Successful trabeculectomies, determined by Kaplan-Meier analysis, in which patients have intraocula
139                                              Kaplan-Meier analysis, including all patients with any s
140                                           By Kaplan-Meier analysis, inclusion of currently unaffected
141                                              Kaplan-Meier analysis indicated a shorter survival time
142                                   Additional Kaplan-Meier analysis indicated that patients on HAART h
143                                              Kaplan-Meier analysis indicated that patients with CED h
144                                              Kaplan-Meier analysis indicates that the current AJCC sy
145 as more likely in group 1 than in group 2 in Kaplan-Meier analysis (Log Rank P=0.04).
146 gher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univa
147 iac risk factors and CMR were significant in Kaplan-Meier analysis (log-rank test, p = 0.0006 and p <
148 icantly with poor survival prognosis using a Kaplan-Meier analysis (log-rank test, P=5 x 10(-4)), sug
149                                              Kaplan-Meier analysis, log-rank tests, Fine and Gray com
150                                           By Kaplan-Meier analysis, median freedom from conduit surge
151 ariate adjusted outcomes were assessed using Kaplan-Meier analysis, multivariate cox regression, mult
152                                              Kaplan-Meier analysis (n=426) demonstrated a cumulative
153                                            A Kaplan-Meier analysis of 45 patients revealed that highe
154      Three prediction methods were compared, Kaplan-Meier analysis of all possible subsets, recursive
155                                              Kaplan-Meier analysis of all the 294 adenocarcinoma nodu
156                                              Kaplan-Meier analysis of beta6 expression in 488 colorec
157                                              Kaplan-Meier analysis of both types of tumors showed tha
158                                              Kaplan-Meier analysis of data from 3455 patients with br
159 ere randomized into eight treatment arms for Kaplan-Meier analysis of defined survival end-point (3.0
160                                              Kaplan-Meier analysis of DFS and OS was performed and in
161                                              Kaplan-Meier analysis of disease-free survival and overa
162                                              Kaplan-Meier analysis of graft and patient survival and
163                                              Kaplan-Meier analysis of graft and patient survival foun
164                               The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemoth
165                                              Kaplan-Meier analysis of metastasis-free survival and ov
166                                              Kaplan-Meier analysis of node-negative and node-positive
167                                              Kaplan-Meier analysis of our population indicated a 1-y
168                                              Kaplan-Meier analysis of overall survival (OS), progress
169                   Descriptive statistics and Kaplan-Meier analysis of overall survival are reported.
170                                              Kaplan-Meier analysis of rates of radiation complication
171                                            A Kaplan-Meier analysis of recurrence-free survival showed
172                                    FINDINGS: Kaplan-Meier analysis of the Kaiser validation cohort sh
173 up vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .7
174                                              Kaplan-Meier analysis of time to first reversal showed a
175                                           By Kaplan-Meier analysis, OS, PFS, and LPFS were lower in p
176                                           In Kaplan-Meier analysis over a 5-year follow-up period, su
177                                           By Kaplan-Meier analysis, overall survival was significantl
178 development of metastases of primary tumors (Kaplan-Meier analysis P = 0.001).
179 ssociated with survival from presentation in Kaplan-Meier analysis (p < 0.01), and loss of 1p36 and 1
180 higher incidence of cardiovascular events by Kaplan-Meier analysis (p = 0.033, log-rank test).
181 eved a 49% increase in tumor growth delay by Kaplan-Meier analysis (P = 0.0367; n = 6).
182 antly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regressi
183                                           By Kaplan-Meier analysis, patients whose pancreatic cancer
184                                        Using Kaplan-Meier analysis, patients with lower DC counts (<
185                                           By Kaplan-Meier analysis, patients with MOLLI-ECV >/= the m
186                                    Survival (Kaplan-Meier) analysis results suggest that the expressi
187                                              Kaplan-Meier analysis revealed a comparable survival pro
188                                              Kaplan-Meier analysis revealed a stepwise increase in mo
189                                              Kaplan-Meier analysis revealed a tendency of AR patients
190                                              Kaplan-Meier analysis revealed event-free survival for s
191                                              Kaplan-Meier analysis revealed no significant difference
192                                              Kaplan-Meier analysis revealed significant mortality bet
193                                              Kaplan-Meier analysis revealed similarly low cardiac eve
194                               Interestingly, Kaplan-Meier analysis revealed that a combined promoter
195 nipulation and no AI at the time of implant, Kaplan-Meier analysis revealed that freedom from greater
196                                              Kaplan-Meier analysis revealed that mortality and cardio
197                                              Kaplan-Meier analysis revealed that patients on hemodial
198                                              Kaplan-Meier analysis revealed that performance of AVR (
199                                              Kaplan-Meier analysis revealed that survival through day
200                                            A Kaplan-Meier analysis revealed that the rates of primary
201                                              Kaplan-Meier analysis revealed the tendency of sleep apn
202                                           In Kaplan-Meier analysis, serum phosphate concentration was
203                                              Kaplan-Meier analysis showed a cumulative incidence of m
204                                              Kaplan-Meier analysis showed a freedom from recurrent em
205                                              Kaplan-Meier analysis showed a mean time of recurrence o
206                                              Kaplan-Meier analysis showed a significant improvement i
207                                              Kaplan-Meier analysis showed a significantly lower event
208                                              Kaplan-Meier analysis showed clear stratification of hig
209                    Twelve months after PIER, Kaplan-Meier analysis showed limb salvage rate was 66%,
210                            Findings from the Kaplan-Meier analysis showed no association between the
211                                              Kaplan-Meier analysis showed no differences in the incid
212                                              Kaplan-Meier analysis showed no significant differences
213                                              Kaplan-Meier analysis showed primary iliofemoral venous
214                                              Kaplan-Meier analysis showed significantly better surviv
215                                              Kaplan-Meier analysis showed similar cancer risks betwee
216                                              Kaplan-Meier analysis showed similar cancer risks betwee
217                                              Kaplan-Meier analysis showed statistically significant d
218                                              Kaplan-Meier analysis showed survival was 78% at 5 years
219                               After 5 years, Kaplan-Meier analysis showed sustained complete remissio
220                                              Kaplan-Meier analysis showed that DM patients had a redu
221                                              Kaplan-Meier analysis showed that dysplasia remained era
222                                              Kaplan-Meier analysis showed that if a high-quality phot
223                    In brain cancer patients, Kaplan-Meier analysis showed that image-derived referenc
224                                              Kaplan-Meier analysis showed that levels of interleukin-
225                                              Kaplan-Meier analysis showed that one- and two-year graf
226                        In ER positive cases, Kaplan-Meier analysis showed that patients with lower mi
227                                              Kaplan-Meier analysis showed that the 1-, 5-, and 10-yea
228                                              Kaplan-Meier analysis showed that the complete success r
229                                            A Kaplan-Meier analysis showed that the probability of dev
230                                              Kaplan-Meier analysis showed that the vaccine group was
231                                              Kaplan-Meier analysis showed worse survival for patients
232                                          The Kaplan-Meier analysis shows a trend toward greater freed
233                                              Kaplan-Meier analysis suggested that neuromonitoring was
234                                              Kaplan-Meier analysis suggests there is at least an addi
235                                           On Kaplan-Meier analysis, the 3-year freedom from ipsilater
236                                           On Kaplan-Meier analysis, the median survival in the entire
237                                         With Kaplan-Meier analysis, the risk of death increased signi
238                               According to a Kaplan-Meier analysis, the time to healing was shorter f
239                                           On Kaplan-Meier analysis there were no differences in short
240                                           By Kaplan-Meier analysis, there was no difference in freedo
241 Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant differen
242                                           In Kaplan-Meier analysis, there was significant variability
243                                      We used Kaplan-Meier analysis to assess disease-specific surviva
244 learance kinetics, measured every 6 h, and a Kaplan-Meier analysis to compare parasite clearance kine
245                                      We used Kaplan-Meier analysis to evaluate the number of cases of
246                            We also conducted Kaplan-Meier analysis to include currently unaffected mu
247                                         In a Kaplan-Meier analysis, two-year and five-year rates of c
248  The associations were further delineated by Kaplan-Meier analysis using publicly available mRNA expr
249                                           By Kaplan-Meier analysis, VA less than 20/200 at 3 years wa
250                   One-year graft survival by Kaplan Meier analysis was 81% and 84% in the AHR and ACR
251                 The 5-year graft survival by Kaplan Meier analysis was better in SA group than in MA
252          Estimated mean survival time in the Kaplan-Meier analysis was 147 months (95% confidence int
253      Median renal survival from diagnosis by Kaplan-Meier analysis was 5.4 years, and median estimate
254      The estimated cumulative CO rates using Kaplan-Meier analysis was 68%.
255                                  Survival by Kaplan-Meier analysis was 77% at 1 year, 62% at 3 years,
256           Five-year disease-free survival on Kaplan-Meier analysis was 82%, and 5-year overall surviv
257                                  Survival by Kaplan-Meier analysis was 94% (SE 0.01), 91% (0.02), and
258                   Median overall survival by Kaplan-Meier analysis was compared between groups using
259                          Patient survival by Kaplan-Meier analysis was higher in hepatitis C-positive
260                                              Kaplan-Meier analysis was performed for censored graft s
261                                              Kaplan-Meier analysis was performed for PTLD-free surviv
262                                              Kaplan-Meier analysis was performed for time to developm
263                                              Kaplan-Meier analysis was performed to compare AZA vs. M
264                                              Kaplan-Meier analysis was performed to compare time to e
265                                              Kaplan-Meier analysis was performed to determine the rel
266                                              Kaplan-Meier analysis was performed to determine the tim
267                                              Kaplan-Meier analysis was performed to estimate the cumu
268                                            A Kaplan-Meier analysis was performed to estimate time to
269                                              Kaplan-Meier analysis was performed to evaluate graft su
270 tory abilities of inflammation-based scores; Kaplan-Meier analysis was performed to plot the survival
271                                              Kaplan-Meier analysis was performed using Criteria A (po
272                        Gene-expression based Kaplan-Meier analysis was performed using The Cancer Gen
273                   Descriptive statistics and Kaplan-Meier analysis was performed.
274 as in patients with limited life expectancy, Kaplan-Meier analysis was repeated including only patien
275                                              Kaplan-Meier analysis was then performed on overall graf
276                                              Kaplan-Meier analysis was used to assess freedom from ne
277 mplications and of need for reoperation, and Kaplan-Meier analysis was used to assess graft survival
278                                              Kaplan-Meier analysis was used to assess ocular outcome
279                                              Kaplan-Meier analysis was used to assess the time betwee
280                                              Kaplan-Meier analysis was used to compute progression-fr
281                                              Kaplan-Meier analysis was used to determine median time
282                                              Kaplan-Meier analysis was used to estimate freedom from
283                                              Kaplan-Meier analysis was used to estimate the cumulativ
284                                              Kaplan-Meier analysis was used to estimate the risk of r
285                                              Kaplan-Meier analysis was used to estimate the time to d
286                                              Kaplan-Meier analysis was used to examine rates of recip
287                                              Kaplan-Meier analysis was used to obtain survival rates.
288 At 1 year, the rate of death from any cause (Kaplan-Meier analysis) was 30.7% with TAVI, as compared
289 l success at the last follow-up according to Kaplan-Meier analysis were 100% and 94.4% in bevacizumab
290     Five-year patient and graft survivals by Kaplan-Meier analysis were significantly lower for type
291                Univariate, multivariate, and Kaplan-Meier analysis were used as appropriate.
292             Cox multivariable regression and Kaplan-Meier analysis were used to identify factors asso
293  [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan-Meier analysis) were 33.9% in the TAVR group and
294 he 1-, 12-, and 24-month mortality rates (by Kaplan-Meier analysis) were 4.5%, 15.8%, and 15.8%, resp
295  CD20+ cells/hpf had worse graft survival in Kaplan-Meier analysis with a hazard ratio 4.56 (CI 1.07-
296                                              Kaplan-Meier analysis with log-rank test was used to det
297     Overall survival (OS) was compared using Kaplan-Meier analysis with log-rank tests and multivaria
298          Overall survival was compared using Kaplan-Meier analysis with log-rank tests, multivariable
299                Univariate Cox regression and Kaplan-Meier analysis with respect to overall survival (
300        With median follow up of 29.1 months, Kaplan-Meier analysis with the log-rank test demonstrate

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top